RAPT Net Income vs Cost Of Revenue Analysis

RAPT Stock

USD 4.04 0.10 2.42%

RAPT Therapeutics financial indicator trend analysis is much more than just breaking down RAPT Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RAPT Therapeutics is a good investment. Please check the relationship between RAPT Therapeutics Net Income and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Net Income vs Cost Of Revenue

Net Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RAPT Therapeutics Net Income account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between RAPT Therapeutics' Net Income and Cost Of Revenue is -0.82. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of RAPT Therapeutics, assuming nothing else is changed. The correlation between historical values of RAPT Therapeutics' Net Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of RAPT Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income i.e., RAPT Therapeutics' Net Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in RAPT Therapeutics financial statement analysis. It represents the amount of money remaining after all of RAPT Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Cost Of Revenue

Cost of Revenue is found on RAPT Therapeutics income statement and represents the costs associated with goods and services RAPT Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from RAPT Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RAPT Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.At this time, RAPT Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 12.53 in 2024, whereas Selling General Administrative is likely to drop slightly above 14.6 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	996K	1.0M	1.1M	944.2K
Total Operating Expenses	73.0M	87.3M	123.5M	71.0M

Reconciled Depreciation Total Operating Expenses

RAPT Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.54	0.81	0.95	0.84	0.89	0.84	0.57	-0.85	0.77	-0.45	0.91	0.9	0.78	1.0	0.91	0.9	-0.75	0.89	0.83	0.95	-0.72	0.95	0.62	1.0	1.0
Other Current Liab	0.54		0.7	0.48	0.43	0.73	0.74	0.18	-0.84	0.78	-0.13	0.74	0.82	0.03	0.53	0.58	0.7	-0.4	0.77	0.35	0.64	-0.34	0.48	0.97	0.53	0.5
Total Current Liabilities	0.81	0.7		0.84	0.91	0.91	0.84	0.36	-0.92	0.95	-0.24	0.87	0.82	0.31	0.8	0.91	0.98	-0.78	0.91	0.82	0.93	-0.73	0.84	0.81	0.8	0.77
Total Stockholder Equity	0.95	0.48	0.84		0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.91	0.95	-0.9	1.0	0.62	0.95	0.94
Other Liab	0.84	0.43	0.91	0.89		0.89	0.68	0.47	-0.83	0.78	-0.39	0.73	0.72	0.45	0.83	0.89	0.92	-0.85	0.87	0.97	0.9	-0.82	0.89	0.59	0.84	0.81
Net Tangible Assets	0.89	0.73	0.91	0.87	0.89		0.78	0.46	-0.97	0.83	-0.4	0.84	0.93	0.44	0.89	0.89	0.95	-0.76	1.0	0.86	0.92	-0.72	0.87	0.83	0.89	0.87
Property Plant And Equipment Net	0.84	0.74	0.84	0.82	0.68	0.78		0.22	-0.82	0.86	-0.06	0.98	0.83	0.52	0.83	0.83	0.87	-0.69	0.8	0.66	0.87	-0.66	0.82	0.77	0.83	0.81
Net Debt	0.57	0.18	0.36	0.41	0.47	0.46	0.22		-0.42	0.42	-0.97	0.34	0.47	0.5	0.58	0.36	0.42	-0.15	0.45	0.41	0.51	-0.12	0.41	0.18	0.58	0.59
Retained Earnings	-0.85	-0.84	-0.92	-0.84	-0.83	-0.97	-0.82	-0.42		-0.9	0.35	-0.87	-0.95	-0.35	-0.84	-0.9	-0.95	0.75	-0.99	-0.77	-0.92	0.7	-0.84	-0.92	-0.84	-0.82
Accounts Payable	0.77	0.78	0.95	0.76	0.78	0.83	0.86	0.42	-0.9		-0.28	0.89	0.83	0.28	0.76	0.86	0.93	-0.67	0.85	0.66	0.91	-0.61	0.76	0.84	0.76	0.73
Cash	-0.45	-0.13	-0.24	-0.31	-0.39	-0.4	-0.06	-0.97	0.35	-0.28		-0.18	-0.39	-0.38	-0.47	-0.26	-0.3	0.1	-0.39	-0.35	-0.39	0.07	-0.31	-0.13	-0.47	-0.48
Non Current Assets Total	0.91	0.74	0.87	0.86	0.73	0.84	0.98	0.34	-0.87	0.89	-0.18		0.9	0.59	0.9	0.89	0.92	-0.69	0.86	0.68	0.93	-0.65	0.86	0.78	0.9	0.88
Non Currrent Assets Other	0.9	0.82	0.82	0.83	0.72	0.93	0.83	0.47	-0.95	0.83	-0.39	0.9		0.53	0.9	0.87	0.9	-0.65	0.95	0.67	0.9	-0.6	0.83	0.86	0.9	0.88
Other Assets	0.78	0.03	0.31	0.68	0.45	0.44	0.52	0.5	-0.35	0.28	-0.38	0.59	0.53		0.79	0.54	0.46	-0.4	0.42	0.5	0.59	-0.41	0.68	0.06	0.79	0.81
Cash And Short Term Investments	1.0	0.53	0.8	0.95	0.83	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79		0.9	0.89	-0.74	0.88	0.82	0.95	-0.71	0.95	0.61	1.0	1.0
Common Stock Total Equity	0.91	0.58	0.91	0.96	0.89	0.89	0.83	0.36	-0.9	0.86	-0.26	0.89	0.87	0.54	0.9		0.96	-0.89	0.9	0.85	0.98	-0.87	0.96	0.72	0.9	0.88
Common Stock Shares Outstanding	0.9	0.7	0.98	0.91	0.92	0.95	0.87	0.42	-0.95	0.93	-0.3	0.92	0.9	0.46	0.89	0.96		-0.81	0.95	0.84	0.98	-0.77	0.91	0.8	0.9	0.87
Non Current Liabilities Total	-0.75	-0.4	-0.78	-0.92	-0.85	-0.76	-0.69	-0.15	0.75	-0.67	0.1	-0.69	-0.65	-0.4	-0.74	-0.89	-0.81		-0.77	-0.89	-0.82	1.0	-0.92	-0.59	-0.75	-0.73
Capital Surpluse	0.89	0.77	0.91	0.87	0.87	1.0	0.8	0.45	-0.99	0.85	-0.39	0.86	0.95	0.42	0.88	0.9	0.95	-0.77		0.83	0.93	-0.72	0.87	0.87	0.88	0.86
Other Current Assets	0.83	0.35	0.82	0.91	0.97	0.86	0.66	0.41	-0.77	0.66	-0.35	0.68	0.67	0.5	0.82	0.85	0.84	-0.89	0.83		0.85	-0.88	0.91	0.53	0.83	0.81
Other Stockholder Equity	0.95	0.64	0.93	0.95	0.9	0.92	0.87	0.51	-0.92	0.91	-0.39	0.93	0.9	0.59	0.95	0.98	0.98	-0.82	0.93	0.85		-0.79	0.95	0.74	0.95	0.93
Total Liab	-0.72	-0.34	-0.73	-0.9	-0.82	-0.72	-0.66	-0.12	0.7	-0.61	0.07	-0.65	-0.6	-0.41	-0.71	-0.87	-0.77	1.0	-0.72	-0.88	-0.79		-0.9	-0.53	-0.72	-0.7
Net Invested Capital	0.95	0.48	0.84	1.0	0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.91	0.95	-0.9		0.62	0.95	0.94
Property Plant And Equipment Gross	0.62	0.97	0.81	0.62	0.59	0.83	0.77	0.18	-0.92	0.84	-0.13	0.78	0.86	0.06	0.61	0.72	0.8	-0.59	0.87	0.53	0.74	-0.53	0.62		0.61	0.58
Total Current Assets	1.0	0.53	0.8	0.95	0.84	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79	1.0	0.9	0.9	-0.75	0.88	0.83	0.95	-0.72	0.95	0.61		1.0
Net Working Capital	1.0	0.5	0.77	0.94	0.81	0.87	0.81	0.59	-0.82	0.73	-0.48	0.88	0.88	0.81	1.0	0.88	0.87	-0.73	0.86	0.81	0.93	-0.7	0.94	0.58	1.0

Click cells to compare fundamentals

RAPT Therapeutics Account Relationship Matchups

RAPT Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Other Current Liab	471K	328K	254K	8.7M	14.2M	14.9M
Total Current Liabilities	9.3M	11.7M	9.6M	14.2M	21.8M	11.7M
Total Stockholder Equity	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Other Liab	969K	2.2M	3.0M	2.7M	3.1M	2.2M
Net Tangible Assets	73.1M	104.2M	186.4M	245.2M	281.9M	296.0M
Property Plant And Equipment Net	3.7M	3.0M	2.7M	9.5M	7.7M	5.1M
Net Debt	(77.4M)	(24.9M)	(24.0M)	(30.0M)	(40.6M)	(42.6M)
Retained Earnings	(162.0M)	(214.8M)	(284.0M)	(367.9M)	(484.7M)	(460.4M)
Accounts Payable	1.1M	2.4M	2.0M	3.4M	5.2M	2.7M
Cash	77.4M	24.9M	24.0M	38.9M	47.5M	37.0M
Non Current Assets Total	4.1M	3.4M	5.7M	13.5M	11.5M	7.1M
Cash And Short Term Investments	77.4M	111.5M	189.7M	249.1M	158.9M	141.1M
Common Stock Shares Outstanding	21.8M	24.1M	27.4M	32.5M	38.3M	27.7M
Liabilities And Stockholders Equity	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Non Current Liabilities Total	2.2M	3.0M	2.7M	6.8M	4.5M	4.2M
Capital Surpluse	235.0M	319.2M	470.6M	613.1M	705.0M	740.3M
Other Current Assets	3.1M	4.1M	3.3M	3.6M	2.9M	3.0M
Other Stockholder Equity	150.4M	319.2M	470.6M	613.1M	631.6M	375.9M
Total Liab	11.5M	14.8M	12.3M	21.0M	26.3M	23.3M
Net Invested Capital	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Property Plant And Equipment Gross	3.7M	3.0M	2.7M	9.5M	17.0M	17.9M
Total Current Assets	80.5M	115.6M	193.0M	252.7M	161.8M	144.1M
Accumulated Other Comprehensive Income	20K	(177K)	(206K)	(26K)	103.0K	108.1K
Net Working Capital	71.3M	103.9M	183.4M	238.5M	139.9M	132.4M
Property Plant Equipment	3.7M	3.0M	2.7M	2.5M	2.3M	2.4M

Pair Trading with RAPT Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if RAPT Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RAPT Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against RAPT Stock

0.51	DSGN	Design Therapeutics	Pair Corr
0.45	OPT	Opthea	Pair Corr

The ability to find closely correlated positions to RAPT Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace RAPT Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back RAPT Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling RAPT Therapeutics to buy it.

The correlation of RAPT Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as RAPT Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if RAPT Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for RAPT Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether RAPT Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if RAPT Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Rapt Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Rapt Therapeutics Stock:

How To Invest In RAPT

Details

Is RAPT Stock a good investment?

Details

What is RAPT Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for RAPT Stock analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities

Is RAPT Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RAPT Therapeutics. If investors know RAPT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RAPT Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.08)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.40)

Return On Equity

(0.67)

The market value of RAPT Therapeutics is measured differently than its book value, which is the value of RAPT that is recorded on the company's balance sheet. Investors also form their own opinion of RAPT Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is RAPT Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RAPT Therapeutics' market value can be influenced by many factors that don't directly affect RAPT Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between RAPT Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if RAPT Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RAPT Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

RAPT Net Income vs Cost Of Revenue Analysis

Net Income vs Cost Of Revenue

Net Income vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Net Income

Cost Of Revenue

RAPT Therapeutics fundamental ratios Correlations

RAPT Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

RAPT Therapeutics fundamental ratios Accounts

Pair Trading with RAPT Therapeutics

Moving against RAPT Stock

Complementary Tools for RAPT Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Surpluse	+ 1.0	Net Tangible Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments

Capital Surpluse	- 0.99	Retained Earnings
Cash	- 0.97	Net Debt
Retained Earnings	- 0.97	Net Tangible Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Non Currrent Assets Other	- 0.95	Retained Earnings
Net Invested Capital	- 0.92	Non Current Liabilities Total